share_log

Vivos Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Vivos Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Vivos Therapeutics | S-3:特定交易註冊聲明
美股sec公告 ·  07/30 06:21
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a medical technology company based in Delaware, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration pertains to the resale of a total of 6,440,532 shares of common stock by the selling stockholder, V-CO Investors LLC, an affiliate of New Seneca Partners, Inc. This includes 169,498 shares of common stock, 3,050,768 shares issuable upon the exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon the exercise of a Common Stock Purchase Warrant. The shares were initially acquired in a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares by the selling stockholder. However, the company may receive funds if the...Show More
Vivos Therapeutics, Inc., a medical technology company based in Delaware, filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on July 29, 2024. The registration pertains to the resale of a total of 6,440,532 shares of common stock by the selling stockholder, V-CO Investors LLC, an affiliate of New Seneca Partners, Inc. This includes 169,498 shares of common stock, 3,050,768 shares issuable upon the exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon the exercise of a Common Stock Purchase Warrant. The shares were initially acquired in a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares by the selling stockholder. However, the company may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS.' The registration statement includes details about the selling stockholder, the plan of distribution, and legal matters, excluding any personal opinions or interpretations, external information, and standard legal terms not directly related to the main event.
總部位於特拉華州的醫療科技公司Vivos Therapeutics, Inc.於2024年7月29日向美國證券交易委員會(SEC)提交了S-3表格登記聲明。此次登記涉及由賣家股東V-CO Investors LLC(新塞尼卡合夥公司的下屬機構)共計6,440,532股普通股的轉售。其中包括169,498股普通股、3,050,768股可通過預先認購權證行權獲得的股票以及3,220,266股可通過普通股購買權證行使獲得的股票。這些股票最初是在2024年6月10日進行的定向增發中獲得的。 Vivos Therapeutics將不會從賣方股東出售的股票中獲得任何收益。但是,如果認購證券以現金形式行使,則該公司可能會獲得資金。這些股票在納斯達克(Nasdaq)資本市場上以“VVOS”爲標的上市。登記聲明包括有關賣方股東、分銷計劃和法律事項的詳細信息,不包括任何個人觀點或解釋、外部信息和與主要事件無直接關聯的標準法律條款。
總部位於特拉華州的醫療科技公司Vivos Therapeutics, Inc.於2024年7月29日向美國證券交易委員會(SEC)提交了S-3表格登記聲明。此次登記涉及由賣家股東V-CO Investors LLC(新塞尼卡合夥公司的下屬機構)共計6,440,532股普通股的轉售。其中包括169,498股普通股、3,050,768股可通過預先認購權證行權獲得的股票以及3,220,266股可通過普通股購買權證行使獲得的股票。這些股票最初是在2024年6月10日進行的定向增發中獲得的。 Vivos Therapeutics將不會從賣方股東出售的股票中獲得任何收益。但是,如果認購證券以現金形式行使,則該公司可能會獲得資金。這些股票在納斯達克(Nasdaq)資本市場上以“VVOS”爲標的上市。登記聲明包括有關賣方股東、分銷計劃和法律事項的詳細信息,不包括任何個人觀點或解釋、外部信息和與主要事件無直接關聯的標準法律條款。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息